References:
1. Dana J, Debray D, Beaufrère A, et al. Cystic fibrosis-related liver
disease: clinical presentations, diagnostic and monitoring approaches in
the era of CFTR modulator therapies. Journal of Hepatology.2022;76(2):420-434.
2. Wu H, Vu M, Dhingra S, et al. Obliterative portal venopathy without
cirrhosis is prevalent in pediatric cystic fibrosis liver disease with
portal hypertension. Clinical Gastroenterology and Hepatology.2019;17(10):2134-2136.
3. Witters P, Libbrecht L, Roskams T, et al. Liver disease in cystic
fibrosis presents as non-cirrhotic portal hypertension. Journal of
Cystic Fibrosis. 2017;16(5):e11-e13.
4. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease
in cystic fibrosis. Hepatology. 1999;30(5):1151-1158.
5. Stonebraker JR, Ooi CY, Pace RG, et al. Features of severe liver
disease with portal hypertension in patients with cystic fibrosis.Clinical Gastroenterology and Hepatology. 2016;14(8):1207-1215.
e1203.
6. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in
cystic fibrosis: a prospective study on incidence, risk factors, and
outcome. Hepatology. 2002;36(6):1374-1382.
7. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, Investigators
FCMGS. Cystic fibrosis liver disease: outcomes and risk factors in a
large cohort of French patients. Hepatology.2019;69(4):1648-1656.
8. Lamireau T, Monnereau S, Martin S, Marcotte J-E, Winnock M, Alvarez
F. Epidemiology of liver disease in cystic fibrosis: a longitudinal
study. Journal of hepatology. 2004;41(6):920-925.
9. Rowland M, Drummond J, Connolly L, et al. The natural history of
cystic fibrosis liver disease a prospective cohort study. Journal
of Cystic Fibrosis. 2023.
10. Vawter GF, Shwachman H. Cystic fibrosis in adults: an autopsy study.Pathology annual. 1979;14:357-382.
11. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice
guidance for the diagnosis and management of cystic fibrosis-associated
liver disease. Journal of Cystic Fibrosis. 2011;10:S29-S36.
12. Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of
ultrasound and biopsy findings in children with cystic fibrosis related
liver disease. Journal of Cystic Fibrosis. 2008;7(3):215-221.
13. Debray D, Narkewicz MR, Bodewes FA, et al. Cystic fibrosis–related
liver disease: research challenges and future perspectives.Journal of pediatric gastroenterology and nutrition.2017;65(4):443-448.
14. CFF.
https://www.cff.org/medical-professionals/patient-registry.
Published 2021. Accessed July 28, 2023.
15. Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA.
Advanced but not mild liver disease is a predictor of decreased survival
in children with cystic fibrosis, with far greater impact in females: A
27-year real-life cohort study. Journal of Cystic Fibrosis.2022;21(2):230-235.
16. Sherwood JS, Ullal J, Kutney K, Hughan KS. Cystic fibrosis related
liver disease and endocrine considerations. Journal of Clinical &
Translational Endocrinology. 2022;27:100283.
17. Chryssostalis A, Hubert D, Coste J, et al. Liver disease in adult
patients with cystic fibrosis: a frequent and independent prognostic
factor associated with death or lung transplantation. Journal of
hepatology. 2011;55(6):1377-1382.
18. Toledano M, Mukherjee S, Howell J, et al. The emerging burden of
liver disease in cystic fibrosis patients: A UK nationwide study.PLoS One. 2019;14(4):e0212779.
19. Koh C, Sakiani S, Surana P, et al. Adult‐onset cystic fibrosis liver
disease: diagnosis and characterization of an underappreciated entity.Hepatology. 2017;66(2):591-601.
20. Martínez-Lázaro AM, Moreno RMG, Seoane FC, et al. Cystic fibrosis
with liver involvement in adults has a benign course. Results from a
tertiary referral centre cohort. Revista espanola de enfermedades
digestivas: organo oficial de la Sociedad Espanola de Patologia
Digestiva. 114.
21. Wood M, Babowicz F, Kennedy AG, et al. Incidence of transaminitis in
adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor.Journal of the American Pharmacists Association.2023;63(3):920-924.
22. Tewkesbury DH, Athwal V, Bright-Thomas RJ, Jones AM, Barry PJ.
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests
at a large single adult cystic fibrosis centre. Journal of Cystic
Fibrosis. 2023;22(2):256-262.
23. Scott J, Jones AM, Piper Hanley K, Athwal VS. epidemiology,
pathogenesis and management of liver disease in adults with cystic
fibrosis. Alimentary Pharmacology & Therapeutics.2022;55(4):389-400.
24. Calvopina DA, Coleman MA, Lewindon PJ, Ramm GA. Function and
regulation of microRNAs and their potential as biomarkers in paediatric
liver disease. International journal of molecular sciences.2016;17(11):1795.
25. Lewindon PJ, Shepherd RW, Walsh MJ, et al. Importance of hepatic
fibrosis in cystic fibrosis and the predictive value of liver biopsy.Hepatology. 2011;53(1):193-201.
26. Maharaj B, Leary W, Naran A, et al. Sampling variability and its
influence on the diagnostic yield of percutaneous needle biopsy of the
liver. The Lancet. 1986;327(8480):523-525.
27. Sellers ZM, Lee LW, Barth RA, Milla C. New algorithm for the
integration of ultrasound into cystic fibrosis liver disease screening.Journal of Pediatric Gastroenterology and Nutrition.2019;69(4):404-410.
28. Loomba R, Adams LA. Advances in non-invasive assessment of hepatic
fibrosis. Gut. 2020;69(7):1343-1352.
29. Karnsakul W, Wasuwanich P, Ingviya T, et al. A longitudinal
assessment of non-invasive biomarkers to diagnose and predict cystic
fibrosis-associated liver disease. Journal of Cystic Fibrosis.2020;19(4):546-552.
30. Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of
serum γ-glutamyltransferase associated with development of cirrhotic
cystic fibrosis liver disease. Journal of Pediatric
Gastroenterology and Nutrition. 2015;61(1):113-118.
31. Leung DH, Khan M, Minard CG, et al. Aspartate aminotransferase to
platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated
pediatric cystic fibrosis liver disease. Hepatology.2015;62(5):1576-1583.
32. Sellers ZM. Barrier to using APRI and GPR as identifiers of cystic
fibrosis liver disease. Journal of Cystic Fibrosis.2021;20(3):551.
33. Calvopina DA, Lewindon PJ, Ramm LE, et al. Gamma-glutamyl
transpeptidase-to-platelet ratio as a biomarker of liver disease and
hepatic fibrosis severity in paediatric cystic fibrosis. Journal
of Cystic Fibrosis. 2022;21(2):236-242.
34. Enaud R, Frison E, Missonnier S, et al. Cystic fibrosis and
noninvasive liver fibrosis assessment methods in children.Pediatric Research. 2022;91(1):223-229.
35. McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R. Performance of
the AST to platelet ratio index (APRI) as a noninvasive marker of
fibrosis in pediatric patients with chronic viral hepatitis.Journal of pediatric gastroenterology and nutrition.2010;50(3):344.
36. Schiavon LL, Schiavon JL, Carvalho Filho RJ, et al. Simple blood
tests as noninvasive markers of liver fibrosis in hemodialysis patients
with chronic hepatitis C virus infection. Hepatology.2007;46(2):307-314.
37. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine
aminotransferase in chronic hepatitis relationship to cirrhosis.Gastroenterology. 1988;95(3):734-739.
38. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on
hepatology practice: past, present and future. Journal of
hepatology. 2022;76(6):1362-1378.
39. Klotter V, Gunchick C, Siemers E, et al. Assessment of pathologic
increase in liver stiffness enables earlier diagnosis of CFLD: results
from a prospective longitudinal cohort study. PloS one.2017;12(6):e0178784.
40. Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP.
Noninvasive methods, including transient elastography, for the detection
of liver disease in adults with cystic fibrosis. Canadian Journal
of Gastroenterology and Hepatology. 2015;29:139-144.
41. Lewindon PJ, Puertolas-Lopez MV, Ramm LE, et al. Accuracy of
transient elastography data combined with APRI in detection and staging
of liver disease in pediatric patients with cystic fibrosis.Clinical Gastroenterology and Hepatology. 2019;17(12):2561-2569.
e2565.
42. Van Biervliet S, Verdievel H, Velde SV, et al. Longitudinal
transient elastography measurements used in follow-up for patients with
cystic fibrosis. Ultrasound in Medicine & Biology.2016;42(4):848-854.
43. Alexopoulou A, Pouriki S, Vasilieva L, et al. Evaluation of
noninvasive markers for the diagnosis of cystic fibrosis liver disease.Scandinavian Journal of Gastroenterology. 2018;53(12):1547-1552.
44. Ling SC, Ye W, Leung DH, et al. Liver ultrasound patterns in
children with cystic fibrosis correlate with non-invasive tests of liver
disease. Journal of pediatric gastroenterology and nutrition.2019;69(3):351.
45. Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR.
Prevalence of elevated liver enzymes in children with cystic fibrosis
diagnosed by newborn screen. Journal of Cystic Fibrosis.2017;16(1):139-145.
46. Middleton PG, Mall MA, Dřevínek P, et al.
Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single
Phe508del allele. New England Journal of Medicine.2019;381(19):1809-1819.
47. Chen Z, Ma Y, Cai J, et al. Serum biomarkers for liver fibrosis.Clinica Chimica Acta. 2022.
48. Pereira TN, Lewindon PJ, Smith JL, et al. Serum markers of hepatic
fibrogenesis in cystic fibrosis liver disease. Journal of
hepatology. 2004;41(4):576-583.
49. Rath T, Menendez KM, Kügler M, et al. TIMP-1/-2 and transient
elastography allow non invasive diagnosis of cystic fibrosis associated
liver disease. Digestive and Liver Disease. 2012;44(9):780-787.
50. Rath T, Hage L, Kügler M, et al. Serum proteome profiling identifies
novel and powerful markers of cystic fibrosis liver disease. PloS
one. 2013;8(3):e58955.
51. Cook NL, Pereira TN, Lewindon PJ, Shepherd RW, Ramm GA. Circulating
microRNAs as noninvasive diagnostic biomarkers of liver disease in
children with cystic fibrosis. Journal of pediatric
gastroenterology and nutrition. 2015;60(2):247-254.
52. Calvopina DA, Chatfield MD, Weis A, et al. MicroRNA sequencing
identifies a serum microRNA panel, which combined with aspartate
aminotransferase to platelet ratio index can detect and monitor liver
disease in pediatric cystic fibrosis. Hepatology.2018;68(6):2301-2316.
53. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The
role of matrix metalloproteinases in cystic fibrosis lung disease.European Respiratory Journal. 2011;38(3):721-727.
54. Galkina SI, Fedorova NV, Ksenofontov AL, et al. Inhibitor of
Hyaluronic Acid Synthesis 4-Methylumbelliferone Suppresses the Secretory
Processes That Ensure the Invasion of Neutrophils into Tissues and
Induce Inflammation. Biomedicines. 2022;10(2):314.
55. Dickinson RS, Murphy F, Doherty C, et al. Pseudomonas expression of
an oxygen sensing prolyl hydroxylase homologue regulates neutrophil host
responses in vitro and in vivo. Wellcome Open Research. 2017;2.
56. Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease
in children. World Journal of Hepatology. 2021;13(11):1727.
57. Leung DH, Narkewicz MR. Cystic fibrosis-related cirrhosis.Journal of Cystic Fibrosis. 2017;16:S50-S61.
58. Lenaerts C, Lapierre C, Patriquin H, et al. Surveillance for cystic
fibrosis-associated hepatobiliary disease: early ultrasound changes and
predisposing factors. The Journal of pediatrics.2003;143(3):343-350.
59. Siegel MJ FA, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J,
Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul
W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM,
Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR;
CFLD Network. Heterogeneous Liver on Research Ultrasound Identifies
Children with Cystic Fibrosis at High Risk of Advanced Liver Disease:
Interim Results of a Prospective Observational Case-Controlled Study.J Pediatr. 2020;219 62-69.e64.
60. Siegel MJ, Leung DH, Molleston JP, et al. Heterogeneous liver on
research ultrasound identifies children with cystic fibrosis at high
risk of advanced liver disease. Journal of Cystic Fibrosis. 2023.
61. Leung DH, Ye W, Schwarzenberg SJ, et al. Long-term follow-up and
liver outcomes in children with cystic fibrosis and nodular liver on
ultrasound in a multi-center study. Journal of Cystic Fibrosis.2023;22(2):248-255.
62. Lam S, Nettel-Aguirre A, Van Biervliet S, et al. Transient
elastography in the evaluation of cystic fibrosis–associated liver
disease: systematic review and meta-analysis. Journal of the
Canadian Association of Gastroenterology. 2019;2(2):71-80.
63. Rowland M, McGee A, Broderick A, et al. Repeatability of transient
elastography in children. Pediatric Research. 2020;88(4):587-592.
64. Calvopina DA, Noble C, Weis A, et al. Supersonic shear-wave
elastography and APRI for the detection and staging of liver disease in
pediatric cystic fibrosis. Journal of Cystic Fibrosis.2020;19(3):449-454.
65. Levitte S, Lee LW, Isaacson J, et al. Clinical use of shear-wave
elastography for detecting liver fibrosis in children and adolescents
with cystic fibrosis. Pediatric radiology. 2021;51:1369-1377.
66. Patel K, Sebastiani G. Limitations of non-invasive tests for
assessment of liver fibrosis. JHEP Reports. 2020;2(2):100067.
67. Dana J, Girard M, Franchi-Abella S, et al. Comparison of Transient
Elastography, ShearWave Elastography, Magnetic Resonance Elastography
and FibroTest as routine diagnostic markers for assessing liver fibrosis
in children with Cystic Fibrosis. Clinics and Research in
Hepatology and Gastroenterology. 2022;46(3):101855.
68. Uchida H, Sakamoto S, Kobayashi M, et al. The degree of spleen
stiffness measured on acoustic radiation force impulse elastography
predicts the severity of portal hypertension in patients with biliary
atresia after portoenterostomy. Journal of pediatric surgery.2015;50(4):559-564.
69. Singh S, Eaton JE, Murad MH, Tanaka H, Iijima H, Talwalkar JA.
Accuracy of spleen stiffness measurement in detection of esophageal
varices in patients with chronic liver disease: systematic review and
meta-analysis. Clinical Gastroenterology and Hepatology.2014;12(6):935-945. e934.
70. Cañas T, Maciá A, Muñoz-Codoceo RA, et al. Hepatic and splenic
acoustic radiation force impulse shear wave velocity elastography in
children with liver disease associated with cystic fibrosis.BioMed research international. 2015;2015.
71. Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic
fibrosis. Gastroenterology Review/Przegląd Gastroenterologiczny.2014;9(3):136-141.
72. Boëlle P-Y, Debray D, Guillot L, Corvol H, Investigators FCMGS.
SERPINA1 Z allele is associated with cystic fibrosis liver disease.Genetics in Medicine. 2019;21(9):2151-2155.
73. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver
disease in cystic fibrosis. Jama. 2009;302(10):1076-1083.
74. Balcar L, Scheiner B, Urheu M, et al. Alpha-1 antitrypsin Pi∗ Z
allele is an independent risk factor for liver transplantation and death
in patients with advanced chronic liver disease. JHEP Reports.2022;4(11):100562.
75. Trouvé P, Génin E, Férec C. In silico search for modifier genes
associated with pancreatic and liver disease in Cystic Fibrosis.PloS one. 2017;12(3):e0173822.
76. Decharatanachart P, Chaiteerakij R, Tiyarattanachai T,
Treeprasertsuk S. Application of artificial intelligence in
non-alcoholic fatty liver disease and liver fibrosis: a systematic
review and meta-analysis. Therapeutic Advances in
Gastroenterology. 2021;14:17562848211062807.
77. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more
accurately classifies steatosis and fibrosis in patients with
nonalcoholic fatty liver disease than transient elastography.Gastroenterology. 2016;150(3):626-637. e627.